

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

In accordance with letter dated
December 6, 2012,

1. Dukes Health System, LLC
d/b/a Dukes Memorial Hospital
2. 275 West 12th Street
Peru, Indiana 46970-1698

3. License No. 13-18703-01

is amended in its entirety to read as follows:

4. Expiration Date: August 31, 2015

5. Docket No. 030-14065

Reference No.

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

A. Any byproduct material permitted by 10 CFR 35.100

A. Any

A. As needed

B. Any byproduct material permitted by 10 CFR 35.200

B. Any

B. As needed

C. Any byproduct material permitted by 10 CFR 35.300

C. Any

C. 2 curies

D. Any byproduct material permitted by 10 CFR 31.11

D. Prepackaged Kits

D. 5 millicuries

E. Depleted Uranium

E. Metal

E. 4 shields not to exceed 25 pounds each

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

D. In vitro studies.

E. For shielding in ADAC Laboratories Transmission Line Source Housing VANTAGE device Model No. MCD/AC.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.

13-18703-01

Docket or Reference No.

030-14065

Amendment No. 23CONDITIONS

10. Licensed material may be used at the licensee's facilities located at 275 West 12th Street, Peru, Indiana.
11. The Radiation Safety Officer (RS) for this license is **Rik Stephens, M.D.**
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized UserMaterial and Use

Marvin Dean Dziabis, M.D.

10 CFR 35.100, 35.200 and 31.11.

Dean Gifford, M.D.

10 CFR 35.100, 35.200 and 31.11.

Rik Stephens, M.D.

10 CFR 35.100, 35.200 and 35.300.

Joseph R. DeCamp, M.D.

10 CFR 35.100, 35.200 and 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries).

Brett A. Hagedorn, M.D.

10 CFR 35.100, 35.200 and 35.300.

John Pasalich, M.D.

10 CFR 35.100, 35.200 and 35.300.

Stephen R. Phillip, M.D.

10 CFR 35.100, 35.200 and 35.300.

Marc Thomas, M.D.

10 CFR 35.100, 35.200 and 35.300.

Diane D. Daly, M.D.

10 CFR 35.100, 35.200 and 35.300.

Frederick N. Vandeman, M.D.

10 CFR 35.100, 35.200 and 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries).

Christopher M. Kowalski, M.D.

10 CFR 35.100 and 35.200.

John L. Bormann, M.D.

10 CFR 35.100, 35.200 and 35.300.

Michael E. Parker, M.D.

10 CFR 35.100, 35.200 and 35.300.

Michael W. Tanksley, M.D.

10 CFR 35.100, 35.200 and 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries).

Andre B. Stovall, M.D.

10 CFR 35.100, 35.200 and 35.300.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.

13-18703-01

Docket or Reference No.

030-14065

Amendment No. 23Authorized UserMaterial and Use

Pamela Lee Strange, M.D.

10 CFR 35.100, 35.200 and 35.300.

John Rock, M.D.

10 CFR 35.100, 35.200 and 35.300.

James C. Wehrenberg, M.D.

10 CFR 35.100 and 35.200.

James A. Arata, M.D.

10 CFR 35.100, 35.200 and 35.300.

David B. Janizek, M.D.

10 CFR 35.100, 35.200 and 35.300.

Christine A. Tremper, M.D.

10 CFR 35.100, 35.200 and 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries).

Randall J. Phillips, M.D.

10 CFR 35.100, 35.200 and 35.300.

John R. Kim, M.D.

10 CFR 35.100, 35.200 and 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries).

Gina W. Hook, M.D.

10 CFR 35.100 and 35.200.

Richard W. Sibley, M.D.

10 CFR 35.100, 35.200 and 35.300.

Dakshesh S. Patel, M.D.

10 CFR 35.100 and 35.200.

Eric V. Heatwole, M.D.

10 CFR 35.100 and 35.200.

Shilpa S. Kashyap, M.D.

10 CFR 35.100 and 35.200.

Deepchand Bajpai, M.D.

10 CFR 35.300.

Rao V. P. Mantravadi, M.D.

10 CFR 35.300.

James Gates, M.D.

10 CFR 35.300.

Stephen Beyer, M.D.

10 CFR 35.300.

Shawn Johnson, M.D.

10 CFR 35.100, 35.200 and 35.300.

Daniel LaMar, M.D.

10 CFR 35.100 and 35.200.

Roderick J. Sawyer, M.D.

10 CFR 35.100 and 35.200.

13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.

13-18703-01

Docket or Reference No.

030-14065

Amendment No. 23

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated February 15, 2005.

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date FEB 12 2013

By _____

Bryan A. Parker
Materials Licensing Branch
Region III